Molecular Cancer Therapeutics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dindo, D.
Right arrow Articles by Clavien, P.-A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dindo, D.
Right arrow Articles by Clavien, P.-A.
Mol Cancer Ther. 2006;5:1520-1529
© 2006 American Association for Cancer Research

Research Articles: Therapeutics

Cationic long-chain ceramide LCL-30 induces cell death by mitochondrial targeting in SW403 cells

Daniel Dindo1, Felix Dahm1, Zdzislaw Szulc2, Alicja Bielawska2, Lina M. Obeid2,3, Yusuf A. Hannun2, Rolf Graf1 and Pierre-Alain Clavien1

1 Swiss HPB (Hepato-Pancreato-Biliary) Center, Department of Visceral and Transplantation Surgery, University Hospital Zurich, Zurich, Switzerland; 2 Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina; and 3 Research Service, Department of Veterans Affairs Medical Center, Charleston, South Carolina

Requests for reprints: Pierre-Alain Clavien, Department of Visceral and Transplantation Surgery, University Hospital Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland. Phone: 41-1-255-33-00; Fax: 41-1-255-44-49. E-mail: clavien{at}chir.unizh.ch

Ceramides are sphingolipid second messengers that are involved in the mediation of cell death. There is accumulating evidence that mitochondria play a central role in ceramide-derived toxicity. We designed a novel cationic long-chain ceramide [{omega}-pyridinium bromide D-erythro-C16-ceramide (LCL-30)] targeting negatively charged mitochondria. Our results show that LCL-30 is highly cytotoxic to SW403 cells (and other cancer cell lines) and preferentially accumulates in mitochondria, resulting in a decrease of the mitochondrial membrane potential, release of mitochondrial cytochrome c, and activation of caspase-3 and caspase-9. Ultrastructural analyses support the concept of mitochondrial selectivity. Interestingly, levels of endogenous mitochondrial C16-ceramide decreased by more than half, whereas levels of sphingosine-1-phosphate increased dramatically and selectively in mitochondria after administration of LCL-30, suggesting the presence of a mitochondrial sphingosine kinase. Of note, intracellular long-chain ceramide levels and sphingosine-1-phosphate remained unaffected in the cytosolic and extramitochondrial (nuclei/cellular membranes) cellular fractions. Furthermore, a synergistic effect of cotreatment of LCL-30 and doxorubicin was observed, which was not related to alterations in endogenous ceramide levels. Cationic long-chain pyridinium ceramides might be promising new drugs for cancer therapy through their mitochondrial preference. [Mol Cancer Ther 2006;5(6):1520–9]


Grant support: Novartis Foundation-Switzerland, Hartmann-Muller Foundation-Switzerland, and EMDO Foundation-Switzerland (D. Dindo), SNF grant 109906 (P-A. Clavien) and NIH grants CA97132 (Y.A. Hannun) and AG16583 (L.M. Obeid).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: D. Dindo and F. Dahm contributed equally to this work.

4 Z. Szulc and A. Bielawska, in preparation.

5 J. Bielawski, Z.M. Szulc, Y.A. Hannun, and A. Bielawska. Methods. In press 2005.

Received 12/12/05; revised 4/ 5/06; accepted 4/21/06.




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. Nocito, F. Dahm, W. Jochum, J. H. Jang, P. Georgiev, M. Bader, R. Graf, and P.-A. Clavien
Serotonin Regulates Macrophage-Mediated Angiogenesis in a Mouse Model of Colon Cancer Allografts
Cancer Res., July 1, 2008; 68(13): 5152 - 5158.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. E. Senkal, S. Ponnusamy, M. J. Rossi, J. Bialewski, D. Sinha, J. C. Jiang, S. M. Jazwinski, Y. A. Hannun, and B. Ogretmen
Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas
Mol. Cancer Ther., February 1, 2007; 6(2): 712 - 722.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
L. Tauzin, C. Graf, M. Sun, P. Rovina, N. Bouveyron, M. Jaritz, A. Winiski, N. Hartmann, F. Staedtler, A. Billich, et al.
Effects of ceramide-1-phosphate on cultured cells: dependence on dodecane in the vehicle
J. Lipid Res., January 1, 2007; 48(1): 66 - 76.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.